Bristol Myers Squibb Forecasts 2024 Adjusted EPS Of $0.75-$0.95 Versus Prior Guidance Of $0.60-$0.90 And Consensus Of $0.71
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb has updated its 2024 financial guidance, raising its adjusted EPS forecast to $0.75-$0.95, above prior guidance and consensus estimates. The company also expects a 5% increase in total revenues and a slight improvement in gross margin.
October 31, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb has increased its 2024 adjusted EPS guidance to $0.75-$0.95, surpassing previous guidance and consensus estimates. The company anticipates a 5% revenue increase and a slight improvement in gross margin.
The updated guidance indicates stronger financial performance than previously expected, which is likely to positively impact investor sentiment and the stock price in the short term. The increase in EPS guidance and revenue growth suggests improved profitability and operational efficiency.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100